Tofacitinib Reduces Inflammation in Down Syndrome Trial
A phase 2 trial found lower inflammation and improvements in some skin conditions among adolescents and adults with Down syndrome who took tofacitinib. Researchers cautioned that the drug is not approved specifically for Down syndrome and that the study cannot establish whether it caused changes in cognitive test results.

Researchers at the Linda Crnic Institute for Down Syndrome found that tofacitinib reduced inflammation in a 16-week trial involving adolescents and adults with Down syndrome, according to their study.
Participants also showed improvements in some inflammatory skin conditions. The findings could inform research into treatments for health conditions associated with Down syndrome, though larger trials are needed.
Tofacitinib is not approved specifically for Down syndrome, and the study does not establish a general treatment recommendation. The phase 2 trial was published in Cell Reports Medicine.
Skin conditions improved during trial
Participants took tofacitinib twice daily for 16 weeks and could opt to continue for 40 weeks. All had inflammatory skin conditions when they enrolled.
The drug blocks signals involved in immune responses and inflammation. Blood tests showed reductions in interferon activity and other markers of inflammation.
Down syndrome is caused by an extra copy of chromosome 21. The chromosome carries genes for receptors for interferons, molecules that regulate immune responses.
Previous research by the Crnic Institute found that the genetic change contributes to chronically elevated interferon signaling. The new trial tested whether reducing that activity could offer a treatment approach.
Researchers documented improvements using clinical scores and measures of skin-related quality of life. Conditions included hidradenitis suppurativa, which causes painful skin lesions, and alopecia areata, an autoimmune condition that causes hair loss.
The study met its predefined safety goal, with a profile similar to that observed in the general population. The findings do not eliminate the drug's known risks, and larger studies are needed to assess long-term safety.
Brain findings need further testing
Participants performed better on selected tests of attention, memory, vocabulary and behavior. Some measures of well-being reported by participants and caregivers also improved.
The trial had no placebo comparison group. Researchers therefore could not determine whether tofacitinib caused those changes or whether other factors, such as practice, played a part.
“The neuropsychological results are intriguing but they are not yet proof that this medicine improves cognition,” said study coauthor Lina Patel, a professor of psychiatry at the University of Colorado Anschutz.
Researchers also observed favorable changes in some biological markers linked to neurological function and Alzheimer's disease. They called for randomized, placebo-controlled studies to assess benefits and longer-term safety.
The team has launched a second trial focused on Down Syndrome Regression Disorder, which involves sudden loss of neurological function. Results are expected in 2027.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →- 1U.S. Emergency Alert Test Nov. 17 Is Not a Power Outage

- 2Michael Clarke Says Sandpapergate Scars Drew Steve Smith to New York

- 3Gold Silver Price November: Futures Rise Near Yearly Lows

- 4GTA 6 New Zealand Time Trick Is Not Guaranteed to Work

- 52027 NFL Mock Draft Puts Ohio State’s Jeremiah Smith at No. 1

Lifestyle · Food & Health4 Reasons to Eat Oatmeal, According to Nutrition Experts
Lifestyle7 Signs Your Social Battery Is Running Low (and Why You Keep Cancelling Plans)
Lifestyle · Food & HealthThanksgiving Food Safety: How Long Leftovers Last and the Safe Turkey Temperature
Lifestyle7 Quiet Habits of Emotionally Intelligent People, According to Psychologists












